Latest filings (excl ownership)
15-12G
Securities registration termination
22 Sep 23
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
22 Sep 23
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
22 Sep 23
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
22 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Sep 23
6-K
IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process
26 Jul 23
25-NSE
Exchange delisting
10 Jul 23
6-K
IMV Receives NASDAQ Delisting Notice
8 May 23
6-K
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
31 Mar 23
6-K
IMV Inc. Announces Changes to Its Board of Directors
27 Mar 23
6-K
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results
16 Mar 23
20-F
2022 FY
Annual report (foreign)
16 Mar 23
6-K
Report of Foreign Private Issuer for the Month of March, 2023
9 Mar 23
6-K
IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial
13 Feb 23
6-K
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S
9 Jan 23
6-K
Current report (foreign)
22 Dec 22
S-8
Registration of securities for employees
21 Dec 22
6-K
Current report (foreign)
20 Dec 22
6-K
IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
20 Dec 22
6-K
Current report (foreign)
20 Dec 22
SUPPL
Supplemental materials (foreign)
20 Dec 22
SUPPL
Supplemental materials (foreign)
19 Dec 22
6-K
IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
16 Dec 22
6-K
IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL
15 Dec 22
6-K
IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split
13 Dec 22
6-K
Report of Foreign Private Issuer for the Month of Decemberer, 2022
7 Dec 22
6-K
IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities
25 Nov 22
6-K
IMV Inc. Announces Third Quarter 2022 Financial and Operational Results
16 Nov 22
6-K
Report of Foreign Private Issuer for the Month of November, 2022
10 Nov 22
6-K
Notice of Special Meeting of Shareholders
28 Oct 22
6-K
Report of Foreign Private Issuer for the Month of October, 2022
12 Oct 22
6-K
Form 51-102F3 Material Change Report
16 Sep 22
6-K
IMV Inc. Announces Strategic Reorganization
15 Sep 22
6-K
IMV Inc. to Present at Two Investor Conferences in September
1 Sep 22
6-K
IMV Inc. Announces Second Quarter 2022 Financial and Operational Results
12 Aug 22
6-K
Report of Foreign Private Issuer for the Month of August, 2022
11 Aug 22
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
3 Feb 23
SC 13G/A
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
21 Jul 21
SC 13G
Venrock Healthcare Capital Partners II, L.P.
30 Jul 20
SC 13G
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
8 May 20
SC 13G/A
Beneficial ownership report (amended)
7 Feb 20
SC 13G
IMV Inc.
13 Feb 19
SC 13D
IMV Inc.
19 Jun 18